Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

Alcon, a leader in eye care, has shown solid performance since its 2019 spin-off, with strong growth prospects and strategic acquisitions enhancing its long-term outlook. The company reported ...

Oppenheimer analyst Steven Lichtman maintained a Buy rating on Alcon (ALC – Research Report) today and set a price target of $105.00. The company’s shares closed yesterday at $96.80.